Key Points
- Moderna insider Shannon Klinger sold 3,471 shares at an average price of $139.95, generating $485,766.45. The transaction was conducted under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, leaving Klinger with 74,129 shares.
- Moderna reported quarterly revenue of $145 million and an adjusted loss of $1.97 per share, beating analyst estimates, while revenue increased 2.1% year over year. Analysts expect a full-year loss of approximately $6.09 per share.
- The stock has a consensus “Hold” rating from analysts, with an average price target of $76.72, considerably below its recent trading level. Institutional investors own approximately 75.33% of Moderna’s outstanding shares.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) insider Shannon Klinger sold 3,471 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares of the company's stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Moderna Trading Down 1.3%
Shares of MRNA stock opened at $148.87 on Friday. The company has a market capitalization of $59.43 billion, a P/E ratio of -18.63 and a beta of 1.10. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $84.18 and a 200 day moving average price of $62.87.
Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.13) earnings per share. Research analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of MRNA. Louisiana State Employees Retirement System bought a new stake in shares of Moderna in the 1st quarter valued at about $899,000. Merck & Co. Inc. bought a new position in Moderna during the 2nd quarter worth approximately $161,642,545. Bank of New York Mellon Corp bought a new position in Moderna during the 2nd quarter worth approximately $119,168,000. Contravisory Investment Management Inc. grew its holdings in Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company's stock valued at $1,696,000 after purchasing an additional 22,590 shares during the period. Finally, Lingotto Investment Management LLP grew its holdings in Moderna by 33.7% during the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company's stock valued at $14,706,000 after purchasing an additional 125,598 shares during the period. 75.33% of the stock is currently owned by institutional investors.
Key Stories Impacting Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna’s Phase 3 INTerpath-001 trial of intismeran autogene with Merck’s Keytruda met its primary recurrence-free-survival endpoint in resected stage IIB–IV melanoma. The result represents the first positive Phase 3 outcome for an mRNA-based cancer therapy and materially strengthens Moderna’s oncology outlook, although detailed data have not yet been released. Moderna cancer vaccine article
- Positive Sentiment: Technical analysts see a bullish pennant forming after the breakout, potentially signaling another advance if the stock clears nearby resistance. Elevated short interest could amplify gains through additional short covering. Moderna bullish pennant forecast
- Positive Sentiment: The FDA approved Moderna’s mFlusiva mRNA flu vaccine for adults, adding a commercial product to the company’s portfolio. Brookline Capital Markets also modestly improved its 2026–2028 EPS forecasts and retained a Buy rating, projecting a return to positive EPS in 2028. FDA approves Moderna flu vaccine
- Neutral Sentiment: Chief legal officer Shannon Klinger sold 3,471 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. Because the sale was planned and tax-related, it offers limited information about management’s view of the stock.
- Negative Sentiment: Rothschild & Co. downgraded Moderna from Neutral to Sell, arguing that the cancer-vaccine rally has left the shares overvalued. Its $81 price target is substantially below the recent trading level, even after being raised from $40. Rothschild Moderna sell rating
- Negative Sentiment: GSK is advancing its own mRNA influenza vaccine into Phase 3 after reporting stronger immune responses in Phase 2. That program could challenge mFlusiva and increase competition in Moderna’s newer commercial market. GSK mRNA flu vaccine development
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. UBS Group set a $81.00 price target on Moderna in a research report on Thursday. William Blair assumed coverage on Moderna in a research report on Friday, August 28th. They issued an "outperform" rating for the company. Piper Sandler reissued an "overweight" rating on shares of Moderna in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on Moderna in a report on Friday, August 28th. They set a "hold" rating on the stock. Finally, Citigroup raised their target price on Moderna from $41.00 to $60.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average price target of $76.72.
Get Our Latest Analysis on Moderna
Moderna Company Profile
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
